Prøve GULL - Gratis
Does The World Need Global Vax Passport?
BioSpectrum Asia
|BioSpectrum Asia July 2021
Governments around the world are exploring the potential benefits of using ‘vaccine passports’ as a way to reopening the economy by identifying and permitting only those who are protected against COVID-19. While the world awaits herd immunity, millions of vaccinated individuals across the world are eagerly anticipating trade and operational plans at the vaccination horizons. Border checkpoints are reviving vigilance around the globe and countries are exploring novel methodologies to revive international travel, an essential social and business component at present.

As the aftermath of the pandemic continues to pummel international trade and businesses across sectors, a concerted attempt is on to develop and deploy potential technologies such as digital and biometric passports. From the second quarter of 2021, travel corridors were opened for vaccinated individuals with the prospect of the ‘digital vaccine certificate/passport’ as an integral part of international travel. Digital vaccine tracking system, the “vaccine passport” is a form of e-certificate that provides proof of vaccination and COVID-19 test results. Yet, they require international or national coordination on the best practices to implement cross-border vaccine passes.
Vaccine passports are not new to the countries who have already used the Yellow card around 1959, a certificate (a physical paper) to identify individuals vaccinated for Yellow fever. A yellow card was mandatory for those arriving from 42 African and South American countries. Nations around the world implemented Yellow Card vaccine passports specifically to complement various border control measures and not just travel. For decades, ‘yellow cards’ were used as proof of vaccination against diseases like cholera, yellow fever, rubella, and polio as a mandatory pass. However, the COVID-19 vaccine passport marks the first electronic alternative. Hence, extending the system to COVID-19 might face hurdles due to the application of digital format and duration of immunity gained by several vaccines administered around the world still under observation.
Tech initiatives
Denne historien er fra BioSpectrum Asia July 2021-utgaven av BioSpectrum Asia.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size